Evidence map›Paper›PMID 42668873›Full record

ReviewDrug design, development and therapy2026

Research Progress of Molecular H

Xiaolin Ding, Wenjie Tang, Yumei Wang, Jinfeng Tian, Jingfei Shi, Youzhen Wei, Chao Cui

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaolin Ding *Department of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, People's Republic of China.
Wenjie Tang *State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.ORCID 0000-0001-6394-3397
Yumei WangHydrogen Medicine Center, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, People's Republic of China.
Jinfeng TianDepartment of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, People's Republic of China.
Jingfei ShiDepartment of Clinical and Basic Medicine, Shandong First Medical University, Jinan, Shandong, People's Republic of China.
Youzhen WeiState Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Chao CuiScientific Research Department, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, People's Republic of China.ORCID 0000-0002-7868-6263

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2025 Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi in recognition of their pioneering contributions to the field of regulatory T cells (Tregs) and peripheral immune tolerance-defining Tregs as the core regulatory subset maintaining immune homeostasis and identifying the transcription factor FOXP3 as decisive for Treg development and functional maintenance, which lays the foundation for elucidating the mechanisms of immune imbalance-related diseases. As a novel bioactive molecule, molecular hydrogen (H

Indexed as

HydrogenImmune ToleranceNobel PrizeT-Lymphocytes, RegulatoryAnimalsAutoimmune DiseasesHumansHydrogenFOXP3hydrogenimmune toleranceoxidative stressTreg

Identifiers

PMID42668873
PMCPMC13525816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.